ConductScience.org, home

Paper21189397

How long have I got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: a systematic review of recent randomized trials.

Kiely BE and 3 others. J Clin Oncol, 2011. Cited by 112 papers, by iCite.

Cite this record

ConductScience Library. How long have I got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: a systematic review of recent randomized trials. Papers, record 21189397. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/21189397

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
How long have I got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: a systematic review of recent randomized trials.
PubMed
Journal
J Clin Oncol
PubMed
Year
2011
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't, Systematic Review
PubMed
Citations, by iCite
112
iCite
Relative citation ratio, by iCite
2.69
iCite
Revised in PubMed
2026-05-13
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Kiely BEBelinda E
2Soon YYYu Yang
3Tattersall MHMartin H N
4Stockler MRMartin R

Source PubMed

Download CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic AgentsMajor topic
Breast NeoplasmsMajor topic
Disease-Free Survival
Female
Humans
Middle Aged
Neoplasm Invasiveness
Randomized Controlled Trials as Topic
Risk Assessment
Risk Factors
Survival Analysis
Survival Rate
Time Factors
Treatment Outcome

Source PubMed

Download CSV of topics

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in21189394Simple rules can improve prognostic accuracy.https://conductscience.org/library/papers/21189394

Source PubMed

Download CSV of comments and corrections

Cited by51

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 112 citations.

PMIDTitleJournalYearIn PapersSource
41613559Ocular metastasis in breast cancer: management of clinical case reports and a literature review.Front Oncol2025https://conductscience.org/library/papers/41613559PubMed
40125267A mixed methods pilot study of a serious illness communication training curriculum among medical residents.Palliat Care Soc Pract2025https://conductscience.org/library/papers/40125267PubMed
39614657Survival scenarios of patients with localized and metastatic pancreatic adenocarcinoma: A population-based study.Int J Cancer2025https://conductscience.org/library/papers/39614657PubMed
38768122Estimating scenarios for survival time in patients with advanced melanoma receiving immunotherapy and targeted therapy.Oncologist2024https://conductscience.org/library/papers/38768122PubMed
37963058Accuracy of oncologists' estimates of expected survival time in advanced cancer.JNCI Cancer Spectr2023https://conductscience.org/library/papers/37963058PubMed
37935631Circulating Tumor Cells Prediction in Hormone Receptor Positive HER2-Negative Advanced Breast Cancer: A Retrospective Analysis of the MONARCH 2 Trial.Oncologist2024https://conductscience.org/library/papers/37935631PubMed
37781156Effect of a prediction tool and communication skills training on communication of treatment outcomes: a multicenter stepped wedge clinical trial (the SOURCE trial).EClinicalMedicine2023https://conductscience.org/library/papers/37781156PubMed
37296790Real-World Outcomes of CDK4/6 Inhibitors Treatment in Metastatic Breast Cancer in Romania.Diagnostics (Basel)2023https://conductscience.org/library/papers/37296790PubMed
37104871A 6-Week Program to Strengthen Resiliency Among Women With Metastatic Cancer: A Randomized Clinical Trial.Oncologist2023https://conductscience.org/library/papers/37104871PubMed
36547132Optimal Choice as First-Line Therapy for Patients with Triple-Negative Breast Cancer: A Bayesian Network Meta-Analysis.Curr Oncol2022https://conductscience.org/library/papers/36547132PubMed
35880940Current State of Cell Therapies for Breast Cancer.Cancer J2022https://conductscience.org/library/papers/35880940PubMed
35871393Voluntary assisted dying: estimating life expectancy to determine eligibility.Med J Aust2022https://conductscience.org/library/papers/35871393PubMed
35701634Using three scenarios to explain life expectancy in advanced cancer: attitudes of patients, family members, and other healthcare professionals.Support Care Cancer2022https://conductscience.org/library/papers/35701634PubMed
35278078Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation.Oncologist2022https://conductscience.org/library/papers/35278078PubMed
34830936Prognostic Value of Prospective Longitudinal CRP to Albumin Ratio among Older Outpatients with Cancer.Cancers (Basel)2021https://conductscience.org/library/papers/34830936PubMed
34553322Does ComPsych Communication Skills Training Alter Trainee Self-Efficacy?Acad Psychiatry2022https://conductscience.org/library/papers/34553322PubMed
34448703Informing Patients With Esophagogastric Cancer About Treatment Outcomes by Using a Web-Based Tool and Training: Development and Evaluation Study.J Med Internet Res2021https://conductscience.org/library/papers/34448703PubMed
34267656Efficacy and Safety of Anti-PD-1/ PD-L1 Monotherapy for Metastatic Breast Cancer: Clinical Evidence.Front Pharmacol2021https://conductscience.org/library/papers/34267656PubMed
34043434Decision Making in Older Adults With Cancer.J Clin Oncol2021https://conductscience.org/library/papers/34043434PubMed
33880062Disparities in Guideline-Concordant Initial Systemic Treatment in Women with HER2-Negative Metastatic Breast Cancer: A SEER-Medicare Analysis.Breast Cancer (Dove Med Press)2021https://conductscience.org/library/papers/33880062PubMed

See all 51 cited byDownload CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ERBB22064PubTator's text mininghttps://conductscience.org/library/genes/2064NCBI Gene
ESR12099PubTator's text mininghttps://conductscience.org/library/genes/2099NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/21189397

GET https://conductscience.org/api/papers/v1/21189397/cited_by?page=2